Our Management Team makes sure we continue to be a successful strategic partner in product development towards intervention strategies against viral diseases. With a broad range of expertise – ranging from virology, immunology to vaccinology – all areas are covered.
CEO
About Byron +
CSO
About Martin +
CFO
About Ruud +Our partners are established companies that are in the very early development stage of vaccines and antivirals for humans and animals.
Ruud van Hofwegen is CFO at Artemis Bioservices, and our financial expert since 2016. With more than a decade of experience in both finance and commerce, he knows what it takes to stay at the forefront of business. As CFO, he ensures the professional execution of our everyday financial management, while keeping a sharp eye on opportunities to take our financial processes to the next level.
Over the years, he has developed a passion for supporting innovative medical and biotech companies by providing full-service solutions and has worked since 2012 for several other med and biotech companies and as of 2016 as a freelancer. He has worked for +15 startups in several consultancy roles. Besides Artemis Bioservices BV, Ruud is working as Finance Director of VarmX, Artica TX, and SPL Medical.
Since 2017 is Byron Martina the CEO of Artemis, where his group focuses on the pathogenesis of emerging viral infections, development of intervention strategies against these diseases, and evaluation of vaccine immunogenicity and efficacy. He studied Biomedical Sciences and graduated as a Master in Infection and Immunity at De Montfort University in Leicester (UK) in 1998. Then he joined the Department of Virology at Erasmus Medical Center in Rotterdam (NL), to obtain his PhD degree in 2003. After his PhD he joined the “Emerging Viruses” team of the same department where he worked on studying the pathogenesis of, and development of intervention strategies against the SARS-Coronavirus. Between 2008 and 2018 he was team leader of the group “exotic viruses” of the Erasmus Medical Center Rotterdam.
Byron has developed and implemented immunogenicity packages within Artemis Bioservices to help map the correlates of protection and demonstrate the efficacy of vaccine or antivirals. He is founder and CEO of AthenaVax B.V, a company that focuses on the development of personalized vaccines against cancer. He has ample experience with the development and use of preclinical animal models and bio-analytical in vitro assays. He supervised eight PhD students. Byron is (co-)author on more than 100 peer reviewed papers, H-index of 37 per 2020.
Martin his experience in virology started in 1990 as researcher in HIV-1/2 basic research. In order to broaden his knowledge in the field of Virology he changed position in 1998 to start working in the field of virus diagnostics. In 2009 he became Head of the unit Clinical Virology and was in this position responsible for finance, HRM and quality of the virus diagnostic portfolio. In January 2015 he started working full time as Director Clinical Services at Viroclinics Biosciences BV with as main responsibilities implementation and maintenance of culture, serological and molecular diagnostic assays, global clinical trial operations business development and client contacts. At the same time he also took up a part time job as assessor ISO15189 for the Dutch Board for Accreditation. By working more than 24 years in both academic and commercial virus diagnostic laboratories he has built up experience in managing an ISO15189 accredited laboratory with more than 40 co-workers and developing and implementation of diagnostic methods and implementing logistic operations for patient management and clinical trials. He has been on missions to the Middle East (Syria/Lebanon/Egypt), West Africa (Cape Verde Isles/Gambia/Guinnee Conakry), Brazil and Indonesia to assist WHO and local governments in evaluating country preparedness for virus outbreaks and was amongst others involved in the global outbreak response for SARS-CoV-1; influenza H1N1pdm09 and Ebola. As consultant he has extensive experience with pre-clinical development; human challenge studies and clinical trial management for antivirals and vaccines. During his career he published more than 125 scientific articles with also senior authorships on articles amongst others in New England Journal of Medicine, Nature, Lancet and Journal of Infectious Diseases.